Aug 06, 2019 Press Release for Alnylam
Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
Aug 06, 2019
− Achieved Second Quarter 2019 ONPATTRO® Global Net Product Revenues of
− Reported Positive Results from ENVISION Phase 3 Study of Givosiran, Submitted Regulatory Filings in the U.S. and EU, and Received Priority Review from
– Completed Enrollment in ILLUMINATE-A Phase 3 Study of Lumasiran and Advanced Multiple Additional Late-Stage Pipeline Programs –
− Formed Broad Collaboration with Regeneron to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases –
− Strengthened Balance Sheet and Ended Second Quarter with Approximately
“Over the past quarter, we’re pleased with the continued strong progress in the global launch of ONPATTRO. We believe that continued commercial execution with ONPATTRO and expected upcoming launches of other products puts us on a path toward attaining self-sustainability in our business, delivering on the promise of RNAi therapeutics for patients around the world,” said
“As we approach the one year anniversary of the ONPATTRO approval, we couldn’t be more proud of our commercial execution. We finished the quarter with over 500 patients on commercial therapy, and we expect continued and steady growth in the years to come driven by new patient finding, global expansion, and additional evidence generation in our ATTR amyloidosis franchise,” said
Second Quarter 2019 and Recent Significant Corporate Highlights
Commercial Performance in Second Quarter 2019
-
Achieved global ONPATTRO net product revenues for the second quarter of 2019 of
$38.2 million . -
Attained more than 500 patients worldwide on commercial ONPATTRO treatment as of
June 30, 2019 . -
Received marketing authorization approvals for ONPATTRO in
Japan andCanada . -
Continued progress with market access efforts across the CEMEA region (Canada, Europe, Middle East, and Africa).
-
Achieved recent reimbursement approvals and favorable ratings from health technology assessment agencies in
England ,Scotland ,Germany ,France ,Canada , andSweden , with significant progress in several additional markets.
-
Achieved recent reimbursement approvals and favorable ratings from health technology assessment agencies in
R&D Highlights
-
Advanced patisiran (the non-branded name for ONPATTRO), an intravenously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis, with plans to initiate the APOLLO-B Phase 3 study in ATTR amyloidosis with cardiomyopathy in mid-2019.
- Presented positive 12-month data from the Global Open-Label Extension (OLE) study, as well as new analyses from the APOLLO Phase 3 study in patients previously treated with tafamidis and results from an indirect treatment comparison of patisiran versus inotersen in hATTR amyloidosis patients with polyneuropathy.
-
Advanced vutrisiran (ALN-TTRsc02), a subcutaneously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis.
- Continued enrollment in the HELIOS-A Phase 3 study of vutrisiran in hereditary ATTR amyloidosis patients with polyneuropathy.
- The Company announces today that it has obtained regulatory alignment on the design of HELIOS-B – a Phase 3 study of vutrisiran in patients with both hereditary and wild-type ATTR amyloidosis cardiomyopathy – which it expects to start in late 2019.
-
Advanced givosiran, an investigational RNAi therapeutic in development for the treatment of acute hepatic porphyria (AHP).
- Presented positive results from the ENVISION Phase 3 study.
-
Completed submissions of a New Drug Application (NDA) with the
U.S. Food and Drug Administration (FDA ) and a Marketing Authorisation Application (MAA) with theEuropean Medicines Agency (EMA); both agencies have accepted the applications for filing. TheFDA also granted the Company’s request for Priority Review and has set an action date ofFebruary 4, 2020 , under the Prescription Drug User Fee Act (PDUFA). At this time, theFDA is not planning to hold an advisory committee meeting to discuss this application. - Alnylam announces today that it has inititated an Expanded Access Program for givosiran to support requests by Health Care Providers for pre-approval access for AHP patients.
-
Advanced lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1).
- Completed enrollment in the ILLUMINATE-A Phase 3 study of lumasiran in PH1 patients six years of age or older with mild-to-moderate renal impairment, and remain on track to report results by year-end 2019.
- Presented complete positive results from the Phase 1/2 clinical study and positive results from the ongoing Phase 2 open-label extension (OLE) study of lumasiran.
- Initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran in PH1 patients under six years of age.
-
Alnylam’s partner, The
Medicines Company , reported new results for inclisiran, an investigational RNAi therapeutic in development for the treatment of hypercholesterolemia.- New data included interim results from the ongoing ORION-3 OLE study in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents and results from the ORION-2 and -7 studies in patients with homozygous familial hypercholesterolemia (HoFH) and in patients with renal impairment, respectively.
-
In addition, The
Medicines Company announced that the Independent Data Monitoring Committee for ongoing inclisiran Phase 3 clinical trials (ORION 9, 10, and 11) completed its seventh planned review of safety and efficacy data from the ORION trials and recommended that the trials continue without modification. The safety database for inclisiran now provides more than 3,500 patient-years of exposure to an RNAi therapeutic, representing the industry’s most comprehensive body of safety data for an RNA therapeutic.
-
Alnylam’s partner,
Sanofi , reported new results from the Phase 2 OLE study of fitusiran, an investigational RNAi therapeutic in development for the treatment of hemophilia. -
Advanced early- and mid-stage RNAi clinical pipeline.
- Initiated a Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure.
- Announced new platform advances, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) directed to a liver target. Oral delivery could broaden the clinical and commercial opportunities for RNAi therapeutics, which are currently administered with intravenous or subcutaneous dose administration.
Additional Business Highlights
-
Formed a broad collaboration with
Regeneron Pharmaceuticals, Inc. (Regeneron) to discover, develop, and commercialize RNAi therapeutics focused on ocular and CNS diseases. -
Concluded the research and option phase of the Company’s 2014 collaboration with
Sanofi focused on advancing RNAi therapeutics for rare genetic diseases. - Entered into a collaboration with 23andMe to support the addition of a new Genetic Health Risk report for Hereditary Amyloidosis (TTR-related). Read more about the report here.
-
Announced senior leadership changes, including the appointment of
Kelley Boucher as the Company’s Senior Vice President, Chief Human Resources Officer; andJeff Poulton as Executive Vice President, Chief Financial Officer, effectiveAugust 13 .
Upcoming Events
In the second half of 2019, Alnylam intends to:
- Initiate the APOLLO-B Phase 3 study of patisiran in ATTR amyloidosis patients with cardiomyopathy in mid-2019.
-
Launch ONPATTRO in
Japan ,England ,Switzerland , and multiple other countries. - Initiate the HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy.
- Initiate the ILLUMINATE-C Phase 3 study of lumasiran in PH1 patients with severe renal impairment.
- Report topline results from the ILLUMINATE-A Phase 3 study of lumasiran in PH1 patients six years of age or older.
In addition, The
Financial Results for the Quarter Ended
“Alnylam had strong financial performance in the second quarter. We ended with cash and cash equivalents on our balance sheet of approximately
“I am thrilled to be joining an organization with great near- and long-term growth prospects driven by advancing innovative therapies with the potential to transform patients’ lives,” said
Cash and Investments
At
In
GAAP and Non-GAAP Net Loss
The net loss according to accounting principles generally accepted in the U.S. (GAAP) for the second quarter of 2019 was
The non-GAAP net loss for the second quarter of 2019 was
Reconciling items between GAAP and non-GAAP net loss include stock-based compensation expense, a gain on the change in fair value of a liability obligation related to the sale of common stock to Regeneron, and a gain on a litigation settlement. See “Use of Non-GAAP Financial Measures” below for a description of non-GAAP financial measures and a reconciliation between GAAP and non-GAAP net loss appearing later in this press release.
ONPATTRO Revenues, Net
Net product revenues from sales of ONPATTRO were
Net Revenues from Collaborators
Net revenues from collaborators were
GAAP research and development (R&D) expenses were
Non-GAAP R&D expenses were
GAAP and Non-GAAP Selling, General and Administrative Expenses
GAAP selling, general and administrative (SG&A) expenses were
Non-GAAP SG&A expenses were
2019 Updated Financial Guidance
Alnylam is updating its 2019 annual non-GAAP R&D expenses to be in the range of
The Company expects its current cash, cash equivalents, and marketable debt securities will support company operations for multiple years based upon its current operating plan.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and non-recurring gains outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in the press release are stock-based compensation expense, a gain on the change in fair value of a liability obligation, and a gain on litigation settlement. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of a gain on the change in fair value of liability obligation and the gain on litigation settlement because the Company believes these items are one-time events occurring outside the ordinary course of the Company’s business.
The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release.
The Company does not provide in this press release a reconciliation of its estimated 2019 non-GAAP R&D and non-GAAP SG&A expense guidance to the comparable GAAP measures because it is not able to estimate 2019 stock-based compensation expense without unreasonable efforts. The Company’s stock-based compensation expense is subject to significant fluctuations from period to period due to variability in the probability of performance-based vesting events for stock options and restricted stock units and changes in the Company’s stock price which materially impact the recognition, timing of expense and fair value of these awards. In addition, the Company believes such reconciliations for its 2019 financial guidance would imply a degree of precision that would be confusing or misleading to investors.
Conference Call Information
Management will provide an update on the Company and discuss second quarter 2019 results as well as expectations for the future via conference call on
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that is approved by the
(
also approved in the
Important Safety Information
ONPATTRO is a medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). ONPATTRO is used in adults only.
Infusion-Related Reactions
Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19 percent of ONPATTRO-treated patients experienced IRRs, compared to 9 percent of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.
To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, paracetamol, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.
Reduced Serum Vitamin A Levels and Recommended Supplementation
ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).
Adverse Reactions
The most common adverse reactions that occurred in patients treated with ONPATTRO were respiratory-tract infections (29 percent) and infusion-related reactions (19 percent).
About LNP Technology
Alnylam has licenses to Arbutus Biopharma LNP intellectual property for use in RNAi therapeutic products using LNP technology.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam’s first commercial RNAi therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU,
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's views with respect to the potential for RNAi therapeutics, including patisiran, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran and ALN-AGT, its expectations with respect to broadened clinical and commercial opportunities enabled by oral delivery of RNAi therapeutics based on preclinical results, its plans for additional evidence generation, global regulatory filings and product launches for ONPATTRO, its expectations regarding pricing and reimbursement procedures outside the U.S., its expectations regarding the timing for the initiation of its APOLLO-B Phase 3 study of patisiran, its plans to initiate the HELIOS-B Phase 3 study for vutrisiran in late 2019, its expectations regarding the regulatory review of givosiran, including the PDUFA date set by the
With the exception of ONPATTRO (patisiran), none of Alnylam’s investigational therapeutics have been approved by the
ALNYLAM PHARMACEUTICALS, INC. |
|||||||||||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS |
|||||||||||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||||||||||
|
|
Three Months Ended
|
|
Six Months Ended
|
|||||||||||||||||||
|
|
|
2019 |
|
|
|
2018 |
|
|
2019 |
|
|
|
2018 |
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
Revenues: |
|
|
|
|
|
|
|
|
|||||||||||||||
Product revenues, net |
|
$ |
|
|
38,231 |
|
$ |
|
— |
|
$ |
|
|
64,522 |
|
$ |
|
— |
|||||
Net revenues from collaborators |
|
|
6,483 |
|
|
|
29,907 |
|
|
13,486 |
|
|
|
51,806 |
|||||||||
Total revenues |
|
|
44,714 |
|
|
|
29,907 |
|
|
78,008 |
|
|
|
51,806 |
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
Cost and expenses: |
|
|
|
|
|
|
|
|
|||||||||||||||
Cost of goods sold |
|
$ |
|
|
4,326 |
|
$ |
|
— |
|
|
7,673 |
|
$ |
|
— |
|||||||
Research and development |
|
|
163,890 |
|
|
|
137,582 |
|
|
293,017 |
|
|
|
234,439 |
|||||||||
Selling, general and administrative |
|
|
112,769 |
|
|
|
84,679 |
|
|
202,377 |
|
|
|
157,126 |
|||||||||
Total costs and expenses |
|
|
280,985 |
|
|
|
222,261 |
|
|
503,067 |
|
|
|
391,565 |
|||||||||
Loss from operations |
|
|
(236,271) |
|
|
|
(192,354) |
|
|
(425,059) |
|
|
|
(339,759) |
|||||||||
Other income (expense): |
|
|
|
|
|
|
|
|
|||||||||||||||
Interest income |
|
|
8,781 |
|
|
|
6,101 |
|
|
16,306 |
|
|
|
11,895 |
|||||||||
Other (expense) income |
|
|
(453) |
|
|
|
2,208 |
|
|
(410) |
|
|
|
2,543 |
|||||||||
Change in fair value of liability obligation |
|
|
9,422 |
|
— |
|
|
9,422 |
|
— |
|||||||||||||
Gain on litigation settlement |
|
— |
|
|
|
20,564 |
|
— |
|
|
|
20,564 |
|||||||||||
Total other income |
|
|
17,750 |
|
|
|
28,873 |
|
|
25,318 |
|
|
|
35,002 |
|||||||||
Loss before income taxes |
|
|
(218,521) |
|
|
|
(163,481) |
|
|
(399,741) |
|
|
|
(304,757) |
|||||||||
Provision for income taxes |
|
|
(960) |
|
|
|
(79) |
|
|
(1,655) |
|
|
|
(17) |
|||||||||
Net loss |
|
$ |
|
|
(219,481) |
|
$ |
|
|
|
(163,560) |
|
$ |
|
|
(401,396) |
|
$ |
|
|
|
(304,774) |
|
Net loss per common share - basic and diluted |
|
$ |
|
|
(2.02) |
|
$ |
|
|
|
(1.63) |
|
$ |
|
|
(3.75) |
|
$ |
|
|
|
(3.04) |
|
Weighted-average common shares used to compute basic and diluted net loss per common share |
|
|
108,576 |
|
|
|
100,519 |
|
|
106,997 |
|
|
|
100,251 |
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
Comprehensive loss: |
|
|
|
|
|
|
|
|
|||||||||||||||
Net loss |
|
$ |
|
|
(219,481) |
|
$ |
|
|
|
(163,560) |
|
$ |
|
|
(401,396) |
|
$ |
|
|
|
(304,774) |
|
Unrealized gain on marketable securities, net of tax |
|
|
462 |
|
|
|
1,046 |
|
|
822 |
|
|
|
626 |
|||||||||
Foreign currency translation |
|
|
842 |
|
— |
|
|
842 |
|
— |
|||||||||||||
Unrealized loss on pension obligation |
|
|
(4,282) |
|
— |
|
|
(4,282) |
|
— |
|||||||||||||
Comprehensive loss |
|
$ |
|
|
(222,459) |
|
$ |
|
|
|
(162,514) |
|
$ |
|
|
(404,014) |
|
$ |
|
|
|
(304,148) |
|
|
|
|
|
|
|
|
|
|
ALNYLAM PHARMACEUTICALS, INC. |
||||||||||||||
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES |
||||||||||||||
(In thousands, except per share amounts) |
||||||||||||||
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||
|
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
||
Reconciliation of GAAP to Non-GAAP Research and development: |
|
|
|
|
|
|
|
|
||||||
GAAP Research and development |
|
$ |
163,890 |
|
$ |
137,582 |
|
$ |
|
293,017 |
|
$ |
234,439 |
|
Less: Stock-based compensation expenses |
|
|
(15,282) |
|
|
(11,616) |
|
|
(31,407) |
|
|
(21,753) |
||
Non-GAAP Research and development |
|
$ |
148,608 |
|
$ |
125,966 |
|
$ |
|
261,610 |
|
$ |
212,686 |
|
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of GAAP to Non-GAAP Selling, general and administrative: |
|
|
|
|
|
|
|
|
||||||
GAAP Selling, general and administrative |
|
$ |
112,769 |
|
$ |
84,679 |
|
$ |
|
202,377 |
|
$ |
157,126 |
|
Less: Stock-based compensation expenses |
|
|
(15,321) |
|
|
(10,625) |
|
|
(31,228) |
|
|
(20,072) |
||
Non-GAAP Selling, general and administrative |
|
$ |
97,448 |
|
$ |
74,054 |
|
$ |
|
171,149 |
|
$ |
137,054 |
|
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of GAAP to Non-GAAP Operating expenses: |
|
|
|
|
|
|
|
|
||||||
GAAP Operating expenses |
|
$ |
280,985 |
|
$ |
222,261 |
|
$ |
|
503,067 |
|
$ |
391,565 |
|
Less: Stock-based compensation expenses |
|
|
(30,603) |
|
|
(22,241) |
|
|
(62,635) |
|
|
(41,825) |
||
Non-GAAP Operating expenses |
|
$ |
250,382 |
|
$ |
200,020 |
|
$ |
|
440,432 |
|
$ |
349,740 |
|
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of GAAP to Non-GAAP Net loss: |
|
|
|
|
|
|
|
|
||||||
GAAP Net loss |
|
$ |
(219,481) |
|
$ |
(163,560) |
|
$ |
|
(401,396) |
|
$ |
(304,774) |
|
Add: Stock-based compensation expenses |
|
|
30,603 |
|
|
22,241 |
|
|
62,635 |
|
|
41,825 |
||
Less: Change in fair value of liability obligation |
|
|
(9,422) |
|
— |
|
|
(9,422) |
|
— |
||||
Less: Gain on litigation settlement |
|
— |
|
|
(20,564) |
|
— |
|
|
(20,564) |
||||
Non-GAAP Net loss |
|
$ |
(198,300) |
|
$ |
(161,883) |
|
$ |
|
(348,183) |
|
$ |
(283,513) |
|
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of GAAP to Non-GAAP Net loss per common share-basic and diluted: |
|
|
|
|
|
|
|
|
||||||
GAAP Net loss per common share - basic and diluted |
|
$ |
(2.02) |
|
$ |
(1.63) |
|
$ |
(3.75) |
$ |
(3.04) |
|||
Add: Stock-based compensation expenses |
|
|
0.28 |
|
|
0.22 |
|
|
0.59 |
|
0.42 |
|||
Less: Change in fair value of liability obligation |
|
|
(0.09) |
|
— |
|
|
(0.09) |
— |
|||||
Less: Gain on litigation settlement |
|
— |
|
|
(0.20) |
|
— |
|
(0.21) |
|||||
Non-GAAP Net loss per common share - basic and diluted |
|
$ |
(1.83) |
|
$ |
(1.61) |
|
$ |
(3.25) |
$ |
(2.83) |
|||
ALNYLAM PHARMACEUTICALS, INC. |
||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
||||
(In thousands, except share amounts) |
||||
|
|
|
||
|
June 30, |
December 31, |
||
|
|
2019 |
|
2018 |
Cash, cash equivalents and marketable debt securities |
$ |
1,926,831 |
$ |
1,082,949 |
Restricted investments |
|
44,825 |
|
44,825 |
Accounts receivable, net |
|
30,739 |
|
18,760 |
Inventory |
|
40,587 |
|
24,068 |
Prepaid expenses and other assets |
|
75,303 |
|
83,542 |
Property, plant and equipment, net |
|
371,769 |
|
320,658 |
Operating lease right-of-use lease assets |
|
226,357 |
— |
|
Total assets |
$ |
2,716,411 |
$ |
1,574,802 |
Accounts payable, accrued expenses and other liabilities |
$ |
219,529 |
$ |
177,392 |
Total deferred revenue |
|
403,129 |
|
3,954 |
Total deferred rent |
— |
|
61,491 |
|
Operating lease liability |
|
306,558 |
— |
|
Long-term debt |
|
30,000 |
|
30,000 |
Total stockholders’ equity (111.1 million shares issued and outstanding at June 30, 2019; 101.2 million shares issued and outstanding at December 31, 2018) |
|
1,757,195 |
|
1,301,965 |
Total liabilities and stockholders' equity |
$ |
2,716,411 |
$ |
1,574,802 |
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam’s Annual Report on Form 10-K which includes the audited financial statements for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005269/en/
Source:
Contacts:
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
For Media Inquiries, please contact:
Christine Lindenboom
SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam